Pure Global
NCT06288906

Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems

Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems in a Monocentric, Observational Retrospective and Prospective Study (ASTER Study)
IRCCS San Raffaele·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thrombosis, Venous
Drug/Device/Intervention
mechanical thrombectomy of caval and iliofemoral veins
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
IRCCS San Raffaele
Location
Milano, Italy
Timeline & enrollment
Phase
N/A
Start date
Mar 30, 2024
End date
Dec 01, 2027
Enrollment
50 participants
Primary outcome

Rate of Technical success,Number of Participants presenting Bleeding

Summary

This is a physician-initiated, observational, monocentric, retrospective and prospective
 Study. The study is intended to assess the feasibility of mechanical thrombectomy of caval
 and iliofemoral veins according to normal clinical practice in adult patients with
 symptomatic acute or subacute ileofemoral or caval deep vein thrombosis objectively diagnosed
 with CT scan imaging.

ICD-10 classifications
Other venous embolism and thrombosisEmbolism and thrombosis of unspecified veinEmbolism and thrombosis of other specified veinsPerianal venous thrombosisArterial embolism and thrombosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06288906
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06288906 through Pure Global AI's free database. This phase not specified trial is sponsored by IRCCS San Raffaele and is currently Not yet recruiting. The study focuses on Thrombosis, Venous. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.